Ethanolamine Oleate

Summary

Ethanolamine Oleate (CHEMBL3989529) is an approved small molecule; indicated across 1 condition including esophageal varices.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 343.5 Da · C20H41NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989529
Name	Ethanolamine Oleate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5282489
Molecular formula	C20H41NO3
Molecular weight	343.5
InChIKey	KGWDUNBJIMUFAP-KVVVOXFISA-N

SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O.C(CO)N

IUPAC name: 2-aminoethanol;(Z)-octadec-9-enoic acid

Also known as: Ethamolin, Ethanolamine oleate, NSC-760382, Oldamin, ETHANOLAMINE OLEATE, Ethanolamine Oleate

Patent coverage: 519 distinct patent families (1,472 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
esophageal varices	4	MONDO:0001221	EFO:0009545

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).